Equities analysts predict that Melinta Therapeutics Inc (NASDAQ:MLNT) will post $17.77 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Melinta Therapeutics’ earnings. The lowest sales estimate is $15.70 million and the highest is $21.10 million. Melinta Therapeutics reported sales of $4.23 million during the same quarter last year, which indicates a positive year-over-year growth rate of 320.1%. The business is scheduled to issue its next earnings results on Tuesday, March 12th.

On average, analysts expect that Melinta Therapeutics will report full year sales of $73.10 million for the current financial year, with estimates ranging from $57.40 million to $93.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $86.95 million, with estimates ranging from $72.90 million to $101.59 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Melinta Therapeutics.

Melinta Therapeutics (NASDAQ:MLNT) last issued its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.55. Melinta Therapeutics had a negative net margin of 202.31% and a negative return on equity of 68.68%. The firm had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $17.24 million.

MLNT has been the subject of a number of research reports. LADENBURG THALM/SH SH reissued a “buy” rating and set a $14.00 target price on shares of Melinta Therapeutics in a research note on Tuesday, December 18th. Zacks Investment Research upgraded shares of Melinta Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Friday, January 4th. Gabelli lowered shares of Melinta Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. HC Wainwright lowered their price target on shares of Melinta Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, October 22nd. Finally, Cantor Fitzgerald set a $15.00 price target on shares of Melinta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Melinta Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.96.

MLNT stock opened at $1.06 on Friday. The stock has a market cap of $58.26 million, a PE ratio of -0.05 and a beta of 2.13. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.34 and a quick ratio of 1.04. Melinta Therapeutics has a 52 week low of $0.64 and a 52 week high of $16.75.

Several institutional investors have recently added to or reduced their stakes in the company. Marshall Wace North America L.P. purchased a new stake in shares of Melinta Therapeutics in the 3rd quarter valued at approximately $48,000. TIAA CREF Investment Management LLC raised its stake in shares of Melinta Therapeutics by 23.7% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 90,646 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 17,360 shares during the period. Boenning & Scattergood Inc. raised its stake in shares of Melinta Therapeutics by 101.1% in the 3rd quarter. Boenning & Scattergood Inc. now owns 47,750 shares of the biotechnology company’s stock valued at $189,000 after acquiring an additional 24,000 shares during the period. ClariVest Asset Management LLC raised its stake in shares of Melinta Therapeutics by 50.0% in the 3rd quarter. ClariVest Asset Management LLC now owns 97,200 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 32,400 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Melinta Therapeutics by 64.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 92,030 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 36,155 shares during the period. 67.56% of the stock is currently owned by institutional investors and hedge funds.

Melinta Therapeutics Company Profile

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.

Further Reading: How do taxes affect a CDs total return?

Get a free copy of the Zacks research report on Melinta Therapeutics (MLNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.